Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease

Blood (2016) 128 (20): 2450–2456.

https://doi.org/10.1182/blood-2016-07-728063

Published: 2016

Includes: Supplemental data

Journal Articles

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Blood (2015) 125 (13): 2068–2074.

https://doi.org/10.1182/blood-2014-12-615187

Published: 2015

Includes: Supplemental data

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

IMWG consensus on maintenance therapy in multiple myeloma

Blood (2012) 119 (13): 3003–3015.

https://doi.org/10.1182/blood-2011-11-374249

Published: 2012

Journal Articles

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

David I. Marks, Tao Wang, Waleska S. Pérez, Joseph H. Antin, Edward Copelan, Robert Peter Gale, Biju George, Vikas Gupta, Joerg Halter, H. Jean Khoury, Thomas R. Klumpp, Hillard M. Lazarus, Victor A. Lewis, Philip McCarthy, David A. Rizzieri, Mitchell Sabloff, Jeff Szer, Martin S. Tallman, Daniel J. Weisdorf

Blood (2010) 116 (3): 366–374.

https://doi.org/10.1182/blood-2010-01-264077

Published: 2010

Includes: Supplemental data

Journal Articles

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Swaminathan Padmanabhan, MD, Anjana Elefante, PharmD, Prakash Varadarajan, MD, Minoo Battiwalla, MD, Arvinder Bir, MD, Theresa Hahn, PhD, Shannon Smiley, MD, Francisco J. Hernandez-Illizalitturi, MD, Loretta Miner, RNP, Alice Mohr, RNP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Philip McCarthy, Jr., MD, Myron Czuczman, MD

Blood (2007) 110 (11): 5130.

https://doi.org/10.1182/blood.V110.11.5130.5130

Published: 2007

Journal Articles

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Philip McCarthy, MD, Joanna M. Panasiewicz, AnneMarie W. Block, Ph.D.

Blood (2004) 104 (11): 4886.

https://doi.org/10.1182/blood.V104.11.4886.4886

Published: 2004

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

Journal Articles

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Alexandra Koryzna, RN, Peter Kouides, MD, Kathleen Donohue, Alice Mohr, NP, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3463.

https://doi.org/10.1182/blood.V104.11.3463.3463

Published: 2004

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Alexandra Koryzna, RN, Kenichi Takeshita, MD, Philip McCarthy, MD, Alice Mohr, NP, Kathleen Donohue, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3476.

https://doi.org/10.1182/blood.V104.11.3476.3476

Published: 2004

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD

Blood (2004) 104 (11): 1396.

https://doi.org/10.1182/blood.V104.11.1396.1396

Published: 2004

Journal Articles

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Laurie A. DiMiceli, Jihnee Yu, Zale P. Bernstein, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 2421.

https://doi.org/10.1182/blood.V104.11.2421.2421

Published: 2004

NARROW

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

IMWG consensus on maintenance therapy in multiple myeloma

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only